RPL17 and melanoma: In clinical trials, relatlimab (anti-LAG-3 monoclonal antibody) combined with nivolumab (anti-PD-1) achieved FDA approval for advanced melanoma (Phase III RELATIVITY-047 trial), demonstrating superior progression-free survival (PFS: 10.1 vs. 4.6 months) (56).